ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 225,80
0,20%
Dow Jones
39 612,74
0,46%
DAX
18 716,42
-0,12%
Brent Oil
82,175
-1,24%
Bitcoin
61 509,61
-2,22%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allogene Therapeutics Inc (ALLO)

  7. Allogene Therapeutics Inc (ALLO) Actualités

ALLO

Allogene Therapeutics (ALLO)

Allogene Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALLO
DateHeureSourceTitreSymboleSociété
13/05/202422h47GlobeNewswire Inc.Allogene Therapeutics Announces Pricing of $110 million Offering of Common StockNASDAQ:ALLOAllogene Therapeutics Inc
13/05/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLOAllogene Therapeutics Inc
13/05/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
13/05/202422h01GlobeNewswire Inc.Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
06/05/202414h30GlobeNewswire Inc.Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
26/04/202414h30GlobeNewswire Inc.Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaNASDAQ:ALLOAllogene Therapeutics Inc
09/04/202414h30GlobeNewswire Inc.Allogene Therapeutics Announces Q2 Investor Conference ParticipationNASDAQ:ALLOAllogene Therapeutics Inc
14/03/202421h05GlobeNewswire Inc.Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
12/03/202413h30GlobeNewswire Inc.Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune DiseaseNASDAQ:ALLOAllogene Therapeutics Inc
05/03/202414h30GlobeNewswire Inc.Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
28/02/202414h30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
16/02/202414h30GlobeNewswire Inc.Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaNASDAQ:ALLOAllogene Therapeutics Inc
31/01/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
22/01/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
16/01/202422h05GlobeNewswire Inc.Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202422h15GlobeNewswire Inc.Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202422h05GlobeNewswire Inc.Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
03/01/202422h05GlobeNewswire Inc.Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
09/12/202318h00GlobeNewswire Inc.Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
01/12/202314h30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in December Investor ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202317h00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202317h00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202321h41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLOAllogene Therapeutics Inc
02/11/202321h02GlobeNewswire Inc.Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202314h00GlobeNewswire Inc.Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
30/10/202313h30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in November Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
26/10/202314h30GlobeNewswire Inc.Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:ALLOAllogene Therapeutics Inc
17/10/202322h34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALLOAllogene Therapeutics Inc
16/10/202314h30GlobeNewswire Inc.Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial OfficerNASDAQ:ALLOAllogene Therapeutics Inc
27/09/202315h09GlobeNewswire Inc.Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLO

Dernières Valeurs Consultées

EU
GLE
Societe Generale
NASDAQ
AAPL
Apple
EU
MC
Lvmh Moet Hennessy Louis...
EU
EN
Bouygues
NYSE
MCD
McDonalds
EU
AI
Air Liquide
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
EU
DG
Vinci
EU
BEL20
Bel 20
EU
ML
Michelin
NYSE
MRK
Merck
EU
BN
Danone
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés